Chan Wing Cheuk, Papaconstantinou Dean, Winnard Doone, Jackson Gary
Population Health, Counties Manukau District Health Board, Auckland, New Zealand
Population Health, Counties Manukau District Health Board, Auckland, New Zealand.
BMJ Open. 2019 Jul 30;9(7):e027291. doi: 10.1136/bmjopen-2018-027291.
To describe the proportions of people dying from abdominal aortic aneurysm (AAA) who might have benefited from a formal screening programme for AAA.
Retrospective cross-sectional review of deaths.
All AAA deaths registered in New Zealand from 2010 to 2014 in the absence of a national AAA screening programme.
Known history of AAA prior to the acute event leading to AAA death, prognosis limiting comorbidities, history of prior abdominal imaging and a validated multimorbidity measure (M3-index scores).
1094 AAA deaths were registered in the 5 years between 2010 and 2014 in New Zealand. Prior to the acute AAA event resulting in death, 31.3% of the cohort had a known AAA diagnosis, and 10.9% had a previous AAA procedure. On average, the AAA diagnosis was known 3.7 years prior to death. At least 77% of the people dying from AAA also had one or more other prognosis limiting diagnosis. The hazard of 1-year mortality associated with the non-AAA related comorbidities for the AAA cohort aged 65 or above were 1.5-2.6 times higher than to the age matched general population based on M3-index scores. In 2014, overall AAA deaths accounted for only 0.7% of total deaths, and 1.0% of deaths among men aged 65 or above in New Zealand. At most, 20% of people dying from AAA in New Zealand between 2010 and 2014 might have had the potential to derive full benefit from a screening programme. About 51% of cases would have derived no or very limited benefit from a screening programme.
Falling AAA mortality, and high prevalence of competing comorbidities and/or prior AAA diagnosis and procedure raises the question about the likely value of a national AAA screening programme in a country such as New Zealand.
描述可能从腹主动脉瘤(AAA)正式筛查项目中受益的因腹主动脉瘤死亡人群的比例。
对死亡情况进行回顾性横断面研究。
2010年至2014年在新西兰登记的所有腹主动脉瘤死亡病例,当时该国尚无全国性腹主动脉瘤筛查项目。
导致腹主动脉瘤死亡的急性事件发生前已知的腹主动脉瘤病史、限制预后的合并症、既往腹部影像学检查史以及经过验证的多种合并症测量指标(M3指数评分)。
2010年至2014年的5年间,新西兰登记了1094例腹主动脉瘤死亡病例。在导致死亡的急性腹主动脉瘤事件发生前,31.3%的队列有已知的腹主动脉瘤诊断,10.9%曾接受过腹主动脉瘤手术。平均而言,腹主动脉瘤诊断在死亡前3.7年已知。至少77%因腹主动脉瘤死亡的人还患有一种或多种其他限制预后的诊断。根据M3指数评分,65岁及以上腹主动脉瘤队列中与非腹主动脉瘤相关合并症相关的1年死亡率风险比年龄匹配的普通人群高1.5至2.6倍。2014年,腹主动脉瘤死亡总数仅占新西兰总死亡人数的0.7%,占65岁及以上男性死亡人数的1.0%。在2010年至2014年期间,新西兰因腹主动脉瘤死亡的人群中,最多20%可能有机会从筛查项目中获得全部益处。约51%的病例从筛查项目中获得的益处为零或非常有限。
腹主动脉瘤死亡率下降,以及存在竞争性合并症和/或既往腹主动脉瘤诊断及手术的高患病率,引发了对于在新西兰这样的国家开展全国性腹主动脉瘤筛查项目可能价值的质疑。